<code id='E6B2F50E63'></code><style id='E6B2F50E63'></style>
    • <acronym id='E6B2F50E63'></acronym>
      <center id='E6B2F50E63'><center id='E6B2F50E63'><tfoot id='E6B2F50E63'></tfoot></center><abbr id='E6B2F50E63'><dir id='E6B2F50E63'><tfoot id='E6B2F50E63'></tfoot><noframes id='E6B2F50E63'>

    • <optgroup id='E6B2F50E63'><strike id='E6B2F50E63'><sup id='E6B2F50E63'></sup></strike><code id='E6B2F50E63'></code></optgroup>
        1. <b id='E6B2F50E63'><label id='E6B2F50E63'><select id='E6B2F50E63'><dt id='E6B2F50E63'><span id='E6B2F50E63'></span></dt></select></label></b><u id='E6B2F50E63'></u>
          <i id='E6B2F50E63'><strike id='E6B2F50E63'><tt id='E6B2F50E63'><pre id='E6B2F50E63'></pre></tt></strike></i>

          
          WSS
          Adobe

          Stoke Therapeutics is still seeking an effective dose for an experimental drug to treat a severe form of childhood epilepsy, following the release of updated data Tuesday that showed disappointing reductions in convulsive seizure activity.

          In the latest look at an ongoing mid-stage study, three monthly injections of the Stoke drug, called STK-001, given at a 45-mg dose, resulted in a median 18% reduction in convulsive seizure activity, compared to baseline.

          advertisement

          The new analysis was conducted on 16 children diagnosed with a rare form of epilepsy called Dravet syndrome. Last November, in six patients, the drug showed a median 55% reduction in seizure activity.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          hotspot